Cleveland BioLabs Announces Appointment of Biotechnology Industry Veteran, Langdon Miller, MD, as President and Chief Medical Officer
05 mai 2015 07h30 HE
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - May 5, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the appointment of Langdon L. Miller, M.D., as President and Chief Medical Officer, effective...
Cleveland BioLabs to Report First Quarter 2015 Financial Results on May 6
30 avr. 2015 07h30 HE
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Apr 30, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on May 6, 2015, it will report its financial results for the first quarter ended March...
Cleveland BioLabs Enters Into Agreement to Raise Up to $4 Million Through Sales of Equity Stake in Incuron Joint Venture
29 avr. 2015 09h54 HE
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Apr 29, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has entered into an agreement to sell its equity stake in Incuron, LLC (Incuron) to Dr....
Cleveland BioLabs and Roswell Park Cancer Institute Announce Award of Department of Defense Breast Cancer Research Program Breakthrough Grant for Entolimod
27 avr. 2015 07h30 HE
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Apr 27, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Roswell Park Cancer Institute (RPCI) today announced the award of a three-year, $1.2 million Breast Cancer...
Cleveland BioLabs Announces Acceptance of Entolimod Phase 1 Study Findings for Poster Presentation at ASCO
22 avr. 2015 09h12 HE
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Apr 22, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that findings from a Phase 1 clinical study of entolimod (previously known as CBLB502) have been...
Cleveland BioLabs Receives Funding Recommendation From Department of Defense for Additional Development Proposal for Entolimod (CBLB502) as a Medical Radiation Countermeasure
14 avr. 2015 07h30 HE
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Apr 14, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company received notice that a second proposal application to support further development...
Cleveland BioLabs Announces New U.S. Composition of Matter Patent for CBLB612
02 avr. 2015 08h00 HE
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Apr 2, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the allowance of a U.S. patent application, to issue as U.S. Patent No. 9,006,183, covering...
Cleveland BioLabs Announces Completion of Dosing in Phase 1 Study of CBLB612 in Russian Federation
16 mars 2015 07h30 HE
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Mar 16, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that a maximally tolerated dose has been reached and that dosing has been completed in a Phase 1...
Cleveland BioLabs and Incuron Announce Growth of Curaxin CBL0137 Patent Portfolio With U.S. Composition of Matter Patent
02 mars 2015 07h30 HE
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Mar 2, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Incuron LLC, a joint venture between the CBLI and Bioprocess Capital Ventures, announce the issuance of a...
Cleveland BioLabs Reports Fourth Quarter and Fiscal 2014 Financial Results and Development Progress
24 févr. 2015 07h30 HE
|
Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwired - Feb 24, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the fourth quarter and fiscal year ended December...